Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.

Q1 Medicine

Current Pathobiology Reports Pub Date : 2019-09-01 Epub Date: 2019-07-25 DOI:10.1007/s40139-019-00202-9

David A Mankoff, Austin R Pantel, Varsha Viswanath, Joel S Karp

{"title":"Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.","authors":"David A Mankoff, Austin R Pantel, Varsha Viswanath, Joel S Karp","doi":"10.1007/s40139-019-00202-9","DOIUrl":null,"url":null,"abstract":"Purpose of the review: We present an overview of recent advances in positron emission tomography (PET) diagnostics as applied to the study of cancer, specifically as a tool to study in vivo cancer biology and to direct targeted cancer therapy. The review is directed to translational and clinical cancer investigators who may not be familiar with these applications of PET cancer diagnostics, but whose research might benefit from these advancing tools.Recent findings: We highlight recent advances in 3 areas: (1) the translation of PET imaging cancer biomarkers to clinical trials; (2) methods for measuring cancer metabolism in vivo in patients; and (3) advances in PET instrumentation, including total-body PET, that enable new methodologies. We emphasize approaches that have been translated to human studies.Summary: PET imaging methodology enables unique in vivo cancer diagnostics that go beyond cancer detection and staging, providing an improved ability to guide cancer treatment and an increased understanding of in vivo human cancer biology.","PeriodicalId":37014,"journal":{"name":"Current Pathobiology Reports","volume":"7 3","pages":"97-108"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117535/pdf/nihms-1887255.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pathobiology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40139-019-00202-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the review: We present an overview of recent advances in positron emission tomography (PET) diagnostics as applied to the study of cancer, specifically as a tool to study in vivo cancer biology and to direct targeted cancer therapy. The review is directed to translational and clinical cancer investigators who may not be familiar with these applications of PET cancer diagnostics, but whose research might benefit from these advancing tools.

Recent findings: We highlight recent advances in 3 areas: (1) the translation of PET imaging cancer biomarkers to clinical trials; (2) methods for measuring cancer metabolism in vivo in patients; and (3) advances in PET instrumentation, including total-body PET, that enable new methodologies. We emphasize approaches that have been translated to human studies.

Summary: PET imaging methodology enables unique in vivo cancer diagnostics that go beyond cancer detection and staging, providing an improved ability to guide cancer treatment and an increased understanding of in vivo human cancer biology.

Abstract Image

查看原文本刊更多论文

用于指导癌症靶向治疗和研究体内癌症生物学的 PET 诊断技术的进展。

综述的目的：我们概述了正电子发射断层扫描 (PET) 诊断应用于癌症研究的最新进展，特别是作为研究体内癌症生物学和指导癌症靶向治疗的工具的最新进展。这篇综述面向转化和临床癌症研究人员，他们可能不熟悉正电子发射断层扫描癌症诊断的这些应用，但他们的研究可能会受益于这些先进的工具：我们重点介绍三个领域的最新进展：(1) 将 PET 成像癌症生物标记物转化为临床试验；(2) 测量患者体内癌症代谢的方法；(3) PET 仪器的进展，包括全身 PET，从而实现新方法。摘要：PET 成像方法实现了超越癌症检测和分期的独特体内癌症诊断，提高了指导癌症治疗的能力，增加了对体内人类癌症生物学的了解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pathobiology Reports Medicine-Pathology and Forensic Medicine

CiteScore

6.40

自引率

0.00%

发文量

期刊介绍： This journal aims to offer expert review articles on the most important recent research pertaining to biological mechanisms underlying disease, including etiology, pathogenesis, and the clinical manifestations of cellular alteration. By providing clear, insightful, balanced contributions, the journal intends to serve those for whom the elucidation of new techniques and technologies related to pathobiology is essential. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of more than 20 internationally diverse members reviews the annual table of contents, ensures that topics include emerging research, and suggests topics of special importance to their country/region. Topics covered may include autophagy, cancer stem cells, induced pluripotential stem cells (iPS cells), inflammation and cancer, matrix pathobiology, miRNA in pathobiology, mitochondrial dysfunction/diseases, and myofibroblast.